Online inquiry

IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12400MR)

This product GTTS-WQ12400MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Crohn's disease (CD), Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12400MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7211MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ14933MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ376MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ11947MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ3806MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ13108MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ606MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ10657MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3819253
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW